Damora Therapeutics, Inc. Common Stock (DMRA) is a publicly traded the market company. As of May 21, 2026, DMRA trades at $23.45 with a market cap of $1.53B and a P/E ratio of 0.00. DMRA moved +0.67% today. Year to date, DMRA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $16.50 to $29.22. Analyst consensus is strong buy with an average price target of $44.40. Rallies surfaces DMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own DMRA include Viking Global. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Damora Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $23.45 |
| Market Cap | $1.53B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $29.22 |
| 52-Week Low | $16.50 |
| Volume | 18 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover DMRA: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.40.